Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 3, 2016, Pages 310-320

  Khan, Taqi A ^a   Hassan, Iftekhar ^b   Ahmad, Ausaf ^c   Perveen, Asma ^d   Aman, Shazia ^d   Quddusi, Saima ^c   Alhazza, Ibrahim M ^b   Ashraf, Ghulam M ^e   Aliev, Gjumrakch ^f,g,h  

^a Sur College of Applied Sciences   (Oman)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c AMITY UNIVERSITY   (India)

^d ALIGARH MUSLIM UNIVERSITY   (India)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^f GALLY International Biomedical Research Consulting LLC   (United States)

^g University of Atlanta   (United States)

^h INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

Author keywords

Aging; Antioxidant proteins; Free radicals; Mitochondrial dysfunction; Neurodegenerative disorders; Oxidative stress

Indexed keywords

ANTIOXIDANT; HYDROGEN PEROXIDE; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

AGING; ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID PEROXIDATION; META ANALYSIS (TOPIC); NERVE DEGENERATION; NEUROSURGERY; NONHUMAN; OXIDATIVE STRESS; PROTEIN AGGREGATION; PROTEIN CARBONYLATION; ANIMAL; DNA DAMAGE; DRUG EFFECTS; ENVIRONMENT; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; ANTIOXIDANTS; DNA DAMAGE; ENVIRONMENT; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84961664669     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160202124518     Document Type: Article

References (172)

1. Hroudová J, Singh N, Fišar Z. Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance to Alzheimer's Disease. Biomed Res Int 2014; 2014: 175062.
2. Mirza Z, Ali A, Ashraf GM, et al. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13: 213-25.
3. Ashraf GM, Greig NH, Khan TA, et al. Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 2014; 13: 1280-93.
4. Fischer R, Maier O. Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF. Oxid Med Cell Longev 2015; 2015: 610813.
5. Li JOW, Li W, et al. Oxidative Stress and Neurodegenerative Disorders. Int J Mol Sci 2013; 14: 24438-75.
6. Radi E, Formichi P, Battisti C, et al. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimer Dis 2014; 42(Suppl 3): S125-52.
7. Zhang R, Zhang Q, Niu J, et al. Screening of microRNAs associated with Alzheimer's disease using oxidative stress cell model and different strains of senescence accelerated mice. J Neurol Sci 2014; 338: 57-64.
8. Uttara B, Singh AV, Zamboni P, et al. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options. Curr Neuropharmacol 2009; 7: 65-74.
9. Fulda S, Gorman AM, Hori O, et al. Cellular Stress Responses: Cell Survival and Cell Death. Int J Cell Biol 2010; 2010: 214074.
10. Rahal A, Kumar A, Singh V, et al. Oxidative Stress, Prooxidants, and Antioxidants: The Interplay. Biomed Res Int 2014; 2014: 761264.
11. Shukla V, Mishra SK, Pant HC. Oxidative Stress in Neurodegeneration. Adv Pharmacol Sci 2011; 2011: 572634.
12. Varçin M, Bentea E, Michotte Y, et al. Oxidative Stress in Genetic Mouse Models of Parkinson’s Disease. Oxid Med Cell Longev 2012; 2012: 624925.
13. Aliev G, Priyadarshini M, Reddy VP, et al. Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of Alzheimer disease. Curr Med Chem 2014; 21: 2208-17.
14. Aliev G, Burzynski G, Ashraf GM, et al. Implication of Oxidative Stress-Induced Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegeneration and Cancer. In: Laher I, Ed. Systems Biology of Free Radicals and Antioxidants. Springer Berlin Heidelberg, 2011; pp. 2325-47.
15. Parmar P. Hazards of Free Radicals in Various Aspects of Health – A Review. J Forens Toxicol Pharmacol 2014; 2014: 03.
16. Berndt N, Holzhütter H-G, Bulik S. Implications of enzyme deficiencies on mitochondrial energy metabolism and reactive oxygen species formation of neurons involved in rotenone-induced Parkinson's disease: a model-based analysis. FEBS J 2013; 280: 5080-93.
17. Lobo V, Patil A, Phatak A, et al. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacog Rev 2010; 4: 118-26.
18. Zhou X, Lu X. The role of oxidative stress in high glucose-induced apoptosis in neonatal rat cardiomyocytes. Exp Biol Med 2013; 238: 898-902.
19. Jabir NR, Firoz CK, Baeesa SS, et al. Synopsis on the linkage of Alzheimer's and Parkinson's disease with chronic diseases. CNS Neurosci Ther 2015; 21: 1-7.
20. Wiggs JL, Yaspan BL, Hauser MA, et al. Common Variants at 9p21 and 8q22 Are Associated with Increased Susceptibility to Optic Nerve Degeneration in Glaucoma. PLoS Genet 2012; 8(4): e1002654.
21. Park SN, Back SA, Choung YH, et al. α-Synuclein deficiency and efferent nerve degeneration in the mouse cochlea: a possible cause of early-onset presbycusis. Neurosci Res 2011; 71: 303-10.
22. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38: 515-7.
23. Kaminsky YG, Reddy VP, Ashraf GM, et al. Age-related defects in erythrocyte 2,3-diphosphoglycerate metabolism in dementia. Aging Dis 2013; 4: 244-55.
24. Kitaoka Y. Tumor necrosis factor-induced optic nerve degeneration and axonal protection. Nippon Ganka Gakkai Zasshi 2013; 117: 878-85.
25. Lesage S, Brice A. Role of mendelian genes in "sporadic" Parkinson's disease. Parkinson Relat Disord 2012; 18(1): S66-70.
26. Petersen AJ, Katzenberger RJ, Wassarman DA. The innate immune response transcription factor relish is necessary for neurodegeneration in a Drosophila model of ataxia-telangiectasia. Genetics 2013; 194: 133-42.
27. Trojanowski JQ, Lee VM. "Fatal attractions" of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. Ann NY Acad Sci 2000; 924: 62-7.
28. Kim KS, Choi SY, Kwon HY, et al. Aggregation of alphasynuclein induced by the Cu,Zn-superoxide dismutase and hydrogen peroxide system. Free Radic Biol Med 2002; 32: 544-50.
29. Price NE, Wadzinski B, Mumby MC. An anchoring factor targets protein phosphatase 2A to brain microtubules. Mol Brain Res 1999; 73: 68-77.
30. Maresca A, la Morgia C, Caporali L, et al. The optic nerve: a "mito-window" on mitochondrial neurodegeneration. Mol Cell Neurosci 2013; 55: 62-76.
31. Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-12.
32. Przedborski S, Vila M, Jackson-Lewis V. Series Introduction: Neurodegeneration: What is it and where are we? J Clin Invest 2003; 111: 3-10.
33. Lill CM, Bertram L. Towards unveiling the genetics of neurodegenerative diseases. Semin Neurol 2011; 31: 531-41.
34. Bosco DA, LaVoie MJ, Petsko GA, et al. Proteostasis and Movement Disorders: Parkinson’s Disease and Amyotrophic Lateral Sclerosis. Cold Spring Harb Perspect Biol 2011; 3(10): a007500.
35. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115: 1449-57.
36. Brown RC, Lockwood AH, Sonawane BR. Neurodegenerative Diseases: An Overview of Environmental Risk Factors. Environ Health Perspect 2005; 113: 1250-6.
37. De Felice A, Ricceri L, Venerosi A, et al. Multifactorial Origin of Neurodevelopmental Disorders: Approaches to Understanding Complex Etiologies. Toxics 2015; 3: 89-129.
38. Campdelacreu J. Parkinson disease and Alzheimer disease: environmental risk factors. Neurologia 2014; 29: 541-9.
39. Migliore L, Coppedè F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 2002; 512: 135-53.
40. Kanthasamy A, Jin H, Anantharam V, et al. Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology 2012; 33: 833-7.
41. Ahmad A, Rasheed N, Ashraf GM, et al. Brain region specific monoamine and oxidative changes during restraint stress. Can J Neurol Sci 2012; 39: 311-8.
42. Ahmad A, Rasheed N, Gupta P, et al. Novel "Ocimum sanctum" compounds modulate stress response: Role of CRF, POMC, GR and HSP-70 in the hypothalamus and pituitary of rats. Med Plants 2013; 5(4): 194-201.
43. Ahmad A, Rasheed N, Gupta P, et al. Novel Ocimumoside A and B as anti-stress agents: modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats. Phytomedicine 2012; 19: 639-47.
44. Aliev G, Horecký J, Vančová O, et al. The Three-Vessel Occlusion as a Model of Vascular Dementia – Oxidative Stress and Mitochondrial Failure as an Indicator of Brain Hypoperfusion. In: Laher I, Ed. Systems Biology of Free Radicals and Antioxidants. Springer Berlin Heidelberg, 2009; pp. 2023-32.
45. Zaidi SK, Ansari SA, Ashraf GM, et al. Reno-protective effect of garlic extract against immobilization stress induced changes in rats. Asia Pacif J Trop Biomed 2015; 5: 364-9.
46. Suhail N, Bilal N, Hasan S, et al. Chronic unpredictable stress (CUS) enhances the carcinogenic potential of 7,12- dimethylbenz(a)anthracene (DMBA) and accelerates the onset of tumor development in Swiss albino mice. Cell Stress Chaper 2015; 20: 1023-36.
47. Hasan S, Suhail N, Bilal N, et al. Chronic unpredictable stress deteriorates the chemopreventive efficacy of pomegranate through oxidative stress pathway. Tumor Biol 2015; Epub ahead of print.
48. Santos CXC, Anilkumar N, Zhang M, et al. Redox signaling in cardiac myocytes. Free Radic Biol Med 2011; 50: 777-93.
49. Camara AKS, Lesnefsky EJ, Stowe DF. Potential Therapeutic Benefits of Strategies Directed to Mitochondria. Antioxid Redox Signal 2010; 13: 279-347.
50. Sharma DR, Sunkaria A, Wani WY, et al. Aluminium induced oxidative stress results in decreased mitochondrial biogenesis via modulation of PGC-1α expression. Toxicol Appl Pharmacol 2013; 273: 365-80.
51. Ashraf GM, Perveen A, Zaidi SK, et al. Studies on the role of goat heart galectin-1 as an erythrocyte membrane perturbing agent. Saudi J Biol Sci 2015; 22: 112-6.
52. Ashraf GM, Perveen A, Tabrez S, et al. Studies on the role of goat heart galectin-1 as a tool for detecting post-malignant changes in glycosylation pattern. Saudi J Biol Sci 2015; 22: 85-9.
53. Ashraf GM, Rizvi S, Naqvi S, et al. Purification, characterization, structural analysis and protein chemistry of a buffalo heart galectin- 1. Amino Acids 2010; 39: 1321-32.
54. Ashraf GM, Banu N, Ahmad A, et al. Purification, characterization, sequencing and biological chemistry of galectin-1 purified from Capra hircus (goat) heart. Protein J 2011; 30: 39-51.
55. Ashraf GM, Perveen A, Zaidi SK, et al. Integrating Qualitative and Quantitative Tools for the Detection and Identification of Lectins in Major Human Diseases. Protein Pept Lett 2015; 22: 954-62.
56. Ashraf GM, Bilal N, Suhail N, et al. Glycosylation of purified buffalo heart galectin-1 plays crucial role in maintaining its structural and functional integrity. Biochem Mosc 2010; 75: 1450-7.
57. Hasan SS, Ashraf GM, Banu N. Galectins – Potential targets for cancer therapy. Cancer Lett 2007; 253: 25-33.
58. Ashraf GM, Perveen A, Tabrez S, et al. Altered galectin glycosylation: potential factor for the diagnostics and therapeutics of various cardiovascular and neurological disorders. Adv Exp Med Biol 2015; 822: 67-84.
59. Diers AR, Broniowska KA, Hogg N. Nitrosative stress and redoxcycling agents synergize to cause mitochondrial dysfunction and cell death in endothelial cells. Redox Biol 2013; 1: 1-7.
60. Nisbet RM, Polanco J-C, Ittner LM, et al. Tau aggregation and its interplay with amyloid-β. Acta Neuropathol 2015; 129: 207-20.
61. Pacher P, Beckman JS, Liaudet L. Nitric Oxide and Peroxynitrite in Health and Disease. Physiol Rev 2007; 87: 315-424.
62. Trachootham D, Lu W, Ogasawara MA, et al. Redox Regulation of Cell Survival. Antioxid. Redox Signal 2008; 10: 1343-74.
63. Hassan I, Chibber S, Khan AA, et al. Cisplatin-induced neurotoxicity in vivo can be alleviated by riboflavin under photoillumination. Cancer Biotherm Radiopharm 2013; 28: 160-8.
64. Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013; 61: 71-90.
65. Villeda SA, Luo J, Mosher KI, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011; 477: 90-4.
66. Frank-Cannon TC, Alto LT, McAlpine FE, et al. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47.
67. Liu J, Johnson TV, Lin J, et al. T cell independent mechanism for copolymer-1-induced neuroprotection. Eur J Immunol 2007; 37: 3143-54.
68. Amor S, Peferoen LAN, Vogel DYS, et al. Inflammation in neurodegenerative diseases--an update. Immunology 2014; 142: 151-66.
69. Stephan AH, Madison DV, Mateos JM, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 2013; 33: 13460-74.
70. Hung C-W, Chen Y-C, Hsieh W-L, et al. Ageing and neurodegenerative diseases. Ageing Res Rev 2010; 9(1): S36-46.
71. Sahin E, Depinho RA. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010; 464: 520-8.
72. Ali A, Sheikh IA, Mirza Z, et al. Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders. Curr Drug Metab 2015; 16(5): 376-88.
73. Fazili NA, Naeem A, Md Ashraf G, et al. Therapeutic Interventions for the Suppression of Alzheimer's disease: Quest for a Remedy. Curr Drug Metab 2015; 16(5): 346-53.
74. Syed Mohd Danish Rizvi SS. Role of anti-diabetic drugs as therapeutic agents in alzheimer's disease. 2015; 14: 684-96.
75. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosur 1992; 76: 53-61.
76. Abeliovich A, Doege CA. Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease. Neuron 2009; 61: 337-9.
77. Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-6.
78. Young AB. Four decades of neurodegenerative disease research: how far we have come! J Neurosci 2009; 29: 12722-8.
79. Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord 2014; 7: 33-51.
80. Fiszer A, Krzyzosiak WJ. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucl Acids Res 2014; 42(11): 6787-810.
81. Rajnish Kumar AS. Classification of oral bioavailability of drugs by machine learning approaches: a comparative study. J Comp Interdisc Sci 2011; 2: 1-18.
82. Shakil S, Ahmad A, Tabrez S, et al. A Region-specific Treatment Strategy To Address The Problem Of Drug Resistance By NDM-1- producing Pathogens. Enzyme Engineer 2013; 2: 1-3.
83. Sharma A, Kumar R, Varadwaj PK, et al. A comparative study of support vector machine, artificial neural network and bayesian classifier for mutagenicity prediction. Interdiscip Sci 2011; 3: 232-9.
84. Jabir NR, Tabrez S, Ashraf GM, et al. Nanotechnology-based approaches in anticancer research. Int J Nanomed 2012; 7: 4391-408.
85. Soursou G, Alexiou A, Ashraf GM, et al. Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer's and Parkinson's Disease. Curr Drug Metab 2015; 16: 705-12.
86. Sheikh IA, Mirza Z, Ali A, et al. A proteomics based approach for the identification of gastric cancer related markers. Curr Pharm Des 2015; In press.
87. Khan NM, Ahmad A, Tiwari RK, et al. Current challenges to overcome in the management of type 2 diabetes mellitus and associated neurological disorders. CNS Neurol Disord Drug Targets 2014; 13: 1440-57.
88. Tabrez S, Priyadarshini M, Urooj M, et al. Cancer chemoprevention by polyphenols and their potential application as nanomedicine. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013; 31: 67-98.
89. Morgan D. Immunotherapy for Alzheimer’s Disease. J Intern Med 2011; 269: 54-63.
90. Hasan S, Bilal N, Naqvi S, et al. Multivitamin-mineral and vitamins (E + C) supplementation modulate chronic unpredictable stress-induced oxidative damage in brain and heart of mice. Biol Trace Element Res 2011; 142: 589-97.
91. Malgieri A, Kantzari E, Patrizi MP, et al. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med 2010; 3: 248-69.
92. Tanna T, Sachan V. Mesenchymal stem cells: potential in treatment of neurodegenerative diseases. Curr Stem Cell Res Ther 2014; 9: 513-21.
93. Joyce N, Annett G, Wirthlin L, et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010; 5: 933-46.
94. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res 2013; 23: 746-58.
95. Duan W. Targeting Sirtuin-1 in Huntington’s disease: Rationale and Current Status. CNS Drugs 2013; 27: 345-52.
96. Aliev G, Ashraf GM, Kaminsky YG, et al. Implication of the nutritional and nonnutritional factors in the context of preservation of cognitive performance in patients with dementia/depression and Alzheimer disease. Am J Alzheimers Dis Other Demen 2013; 28: 660-70.
97. Kumar H, Lim H-W, More SV, et al. The role of free radicals in the aging brain and Parkinson's disease: convergence and parallelism. Int J Mol Sci 2012; 13: 10478-504.
98. Ienco EC, LoGerfo A, Carlesi C, et al. Oxidative stress treatment for clinical trials in neurodegenerative diseases. J Alzheimer Dis 2011; 24(2): 111-26.
99. Dashtipour K, Liu M, Kani C, et al. Iron Accumulation Is Not Homogenous among Patients with Parkinson's Disease. Parkinson Dis 2015; 2015.
100. Qureshi GA, Memon SA, Memon AB, et al. The emerging role of iron, zinc, copper, magnesium and selenium and oxidative stress in health and diseases. Biogen Amines 2005; 19: 147-69.
101. Zheng W, Monnot AD. Regulation of Brain Iron and Copper Homeostasis by Brain Barrier Systems: Implication in Neurodegenerative Diseases. Pharmacol Ther 2012; 133: 177-88.
102. Ganz T. Systemic Iron Homeostasis. Physiol Rev 2013; 93: 1721-41.
103. Love S. Demyelinating diseases. J Clin Pathol 2006; 59: 1151-9.
104. Hoffmann DB, Williams SK, Bojcevski J, et al. Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. J Neuropathol Exp Neurol 2013; 72: 745-57.
105. Ohta E, Takiyama Y. MRI Findings in Neuroferritinopathy. Neurol Res Int 2012; 2012: 197438.
106. Choonara YE, Pillay V, du Toit LC, et al. Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders. Int J Mol Sci 2009; 10: 2510-57.
107. Turnbull S, Tabner BJ, El-Agnaf OM, et al. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic Biol Med 2001; 30: 1163-70.
108. Sugiyama Y, Suzuki T, Yates BJ. Role of the Rostral Ventrolateral Medulla (RVLM) in the Patterning of Vestibular System Influences on Sympathetic Nervous System Outflow to the Upper and Lower Body. Exp Brain Res 2011; 210: 515-27.
109. Shinohara K, Hirooka Y, Kishi T, et al. Reduction of nitric oxidemediated γ -amino butyric acid release in rostral ventrolateral medulla is involved in superoxide-induced sympathoexcitation of hypertensive rats. Circul J 2012; 76: 2814-21.
110. Kishi T, Hirooka Y. Oxidative stress in the brain causes hypertension via sympathoexcitation. Front Physiol 2012; 3: 335.
111. Fernández-Blanco E, Aguiar-Pulido V, Munteanu CR, et al. Random Forest classification based on star graph topological indices for antioxidant proteins. J Ther Biol 2013; 317: 331-7.
112. Elias RJ, Kellerby SS, Decker EA. Antioxidant activity of proteins and peptides. Crit Rev Food Sci Nutr 2008; 48: 430-41.
113. Lee WL, Huang JY, Shyur LF. Phytoagents for Cancer Management: Regulation of Nucleic Acid Oxidation, ROS, and Related Mechanisms. Oxid Med Cell Longev 2013; 2013: 925804.
114. Salil G, Nevin KG, Rajamohan T. Coconut kernel-derived proteins enhance hypolipidemic and antioxidant activity in alloxan-induced diabetic rats. Int J Food Sci Nutr 2013; 64: 327-32.
115. Oh NS, Lee HA, Lee JY, et al. The dual effects of Maillard reaction and enzymatic hydrolysis on the antioxidant activity of milk proteins. J Dairy Sci 2013; 96: 4899-911.
116. Zhang H, Jiang L, Guo H, et al. The inhibitory effect of milk on the absorption of dietary phenolic acids and the change in human plasma antioxidant capacity through a mechanism involving both milk proteins and fats. Mol Nutr Food Res 2013; 57: 1228-36.
117. Conway V, Gauthier SF, Pouliot Y. Antioxidant Activities of Buttermilk Proteins, Whey Proteins, and Their Enzymatic Hydrolysates. J Agric Food Chem 2013; 61: 364-72.
118. Reddy PH, Mao P, Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res Rev 2009; 61: 33-48.
119. Feissner RF, Skalska J, Gaum WE, et al. Crosstalk signaling between mitochondrial Ca2+ and ROS. Front Biosci 2009; 14: 1197-218.
120. Aliev G, Ashraf GM, Horecký J, et al. Potential Preventive Effects of Coenzyme Q and Creatine Supplementation on Brain Energy Metabolism in Rats Exposed to Chronic Cerebral Hypoperfusion. In: Laher I, Ed. Systems Biology of Free Radicals and Antioxidants. Springer Berlin Heidelberg, 2011; pp. 2033-48.
121. Cui H, Kong Y, Zhang H. Oxidative Stress, Mitochondrial Dysfunction, and Aging. J Signal Trans 2012; 2012: 646354.
122. Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol 2007; 35: 495-516.
123. de Moura MB, dos Santos LS, Van Houten B. Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen 2010; 51: 391-405.
124. Chatterjee A, Dasgupta S, Sidransky D. Mitochondrial Subversion in Cancer. Cancer Prev Res 2011; 4: 638-54.
125. Rahman K. Studies on free radicals, antioxidants, and co-factors. Clin Interv Aging 2007; 2: 219-36.
126. Garc, XED, A-Escudero V, et al. Deconstructing Mitochondrial Dysfunction in Alzheimer Disease. Oxid Med Cell Longev 2013; 2013: 162152.
127. Tang Y-P, Gershon ES. Genetic studies in Alzheimer's disease. Dial Clin Neurosci 2003; 5: 17-26.
128. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochem Biophys Acta 2010; 1802: 29-44.
129. Damiano M, Galvan L, Déglon N, et al. Mitochondria in Huntington's disease. Biochem Biophys Acta 2010; 1802: 52-61.
130. Reddy PH. Mitochondrial Medicine for Aging and Neurodegenerative Diseases. Neuromol Med 2008; 10: 291-315.
131. Reddy PH, Reddy TP. Mitochondria as a therapeutic target for aging and neurodegenerative diseases. Curr Alzheimer Res 2011; 8: 393-409.
132. Kolesnikova EÉ. Mitochondrial Dysfunction and Molecular Bases of Neurodegenerative Diseases. Neurophysiology 2013; 45: 89-102.
133. Solís-Herrera A, Ashraf GM, del CA Esparza M, et al. Biological Activities of QIAPI 1 as a Melanin Precursor and Its Therapeutic Effects in Wistar Rats Exposed to Arsenic Poisoning. CNS Agents Med Chem 2015; 15: 99-108.
134. Herrera AS, Del C A Esparza M, Md Ashraf G, et al. Beyond mitochondria, what would be the energy source of the cell? CNS Agents Med Chem 2015; 15: 32-41.
135. Sung C-C, Hsu Y-C, Chen C-C, et al. Oxidative Stress and Nucleic Acid Oxidation in Patients with Chronic Kidney Disease. Oxid Med Cell Longev 2013; 2013: 301982.
136. Asano T, Koike M, Sakata S-I, et al. Possible involvement of ironinduced oxidative insults in neurodegeneration. Neurosci Lett 2015; 588: 29-35.
137. Bizzozero OA, Reyes S, Ziegler J, et al. Lipid peroxidation scavengers prevent the carbonylation of cytoskeletal brain proteins induced by glutathione depletion. Neurochem Res 2007; 32: 2114-22.
138. Dalle-Donne I, Giustarini D, Colombo R, et al. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-76.
139. Dasgupta A, Zheng J, Bizzozero OA. Protein carbonylation and aggregation precede neuronal apoptosis induced by partial glutathione depletion. ASN Neurol 2012; 4(3): pii: e00084.
140. Persson TXFRN, et al. Oxidative Stress in Alzheimer's Disease: Why Did Antioxidant Therapy Fail? Oxid Med Cell Longev 2014; 2014: 427318.
141. Ayala A, Mu, XF, et al. Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal. Oxid Med Cell Longev 2014; 2014: 360438.
142. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
143. Perluigi M, Coccia R, Butterfield DA. 4-Hydroxy-2-Nonenal, a Reactive Product of Lipid Peroxidation, and Neurodegenerative Diseases: A Toxic Combination Illuminated by Redox Proteomics Studies. Antioxid Redox Signal 2012; 17: 1590-609.
144. Chen X, Guo C, Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen Res 2012; 7: 376-85.
145. Sultana R, Cenini G, Butterfield DA. Biomarkers of Oxidative Stress in Neurodegenerative Diseases. In: Villamena FA, Ed. Molecular Basis of Oxidative Stress. John Wiley & Sons, Inc., 2013; pp. 359-76.
146. Kovacic P, Somanathan R. Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species. Curr Neuropharmacol 2012; 10: 289-302.
147. Poljsak BX, Uput D, et al. Achieving the Balance between ROS and Antioxidants: When to Use the Synthetic Antioxidants. Oxid Med Cell Longev 2013; 2013: 956792.
148. von Arnim CAF, Gola U, Biesalski HK. More than the sum of its parts? Nutrition in Alzheimer's disease. Nutrition 2010; 26: 694-700.
149. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence? Nat Med 2004; 10: S18-25.
150. Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta 1998; 1366: 53-67.
151. Wang Y-H, Xuan Z-H, Tian S, et al. Echinacoside Protects against 6-Hydroxydopamine-Induced Mitochondrial Dysfunction and Inflammatory Responses in PC12 Cells via Reducing ROS Production. Evid Based Complement Alternat Med 2015; 2015: 189239.
152. Jellinger K, Paulus W, Grundke-Iqbal I, et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Trans Parkin Dis Dement Sect 1990; 2: 327-40.
153. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000; 29: 222-30.
154. Fernández-Checa JC, Fernández A, Morales A, et al. Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol Disord Drug Targets 2010; 9: 439-54.
155. Ferreiro E, Baldeiras I, Ferreira IL, et al. Mitochondrial- and Endoplasmic Reticulum-Associated Oxidative Stress in Alzheimer's Disease: From Pathogenesis to Biomarkers. Int J Cell Biol 2012; 2012: 735206.
156. de Oliveira DM, Ferreira Lima RM, El-Bachá RS. Brain rust: recent discoveries on the role of oxidative stress in neurodegenerative diseases. Nutr Neurosci 2012; 15: 94-102.
157. Rikans LE, Hornbrook KR. Lipid peroxidation, antioxidant protection and aging. Biochim Biophys Acta 1997; 1362: 116-27.
158. Oesch F. Metabolism of carcinogens, possibilities for modulation. Acta Pharmacol Toxicol 1984; 55(Suppl 2): 15-33.
159. Saeidnia S, Abdollahi M. Toxicological and pharmacological concerns on oxidative stress and related diseases. Toxicol Appl Pharmacol 2013; 273: 442-55.
160. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 2010; 1802: 66-79.
161. Shin S-G, Kim JY, Chung HY, et al. Zingerone as an antioxidant against peroxynitrite. J Agric Food Chem 2005; 53: 7617-22.
162. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005; 7: 685-93.
163. Valko M, Rhodes CJ, Moncol J, et al. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 2006; 160: 1-40.
164. Afanas’ev I. Signaling and Damaging Functions of Free Radicals in Aging—Free Radical Theory, Hormesis, and TOR. Aging Dis 2010; 1: 75-88.
165. Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci 2011; 12: 359-66.
166. Acquatella-Tran Van Ba I, Imberdis T, Perrier V, et al. From Prion Diseases to Prion-Like Propagation Mechanisms of Neurodegenerative Diseases. Int J Cell Biol 2013; 2013: 975832.
167. Yuan F, Yang L, Zhang Z, et al. Cellular prion protein (PrPC) of the neuron cell transformed to a PK-resistant protein under oxidative stress, comprising main mitochondrial damage in prion diseases. J Mol Neurosci 2013; 51: 219-24.
168. Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 1997; 18: 431-5.
169. Jossan SS, Gillberg PG, d’Argy R, et al. Quantitative localization of human brain monoamine oxidase B by large section autoradiography using L-[3H]deprenyl. Brain Res 1991; 547: 69-76.
170. Klein LC, Passos CSD, Moraes AP, et al. Indole alkaloids and semisynthetic indole derivatives as multifunctional scaffolds aiming the inhibition of enzymes related to neurodegenerative diseases--a focus on Psychotria L. Genus. Curr Top Med Chem 2014; 14: 1056-75.
171. Tam WY, Ma CHE. Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes. Sci Rep 2014; 4: 7279.
172. Lull ME, Block ML. Microglial Activation & Chronic Neurodegeneration. Neurotherapeutics 2010; 7: 354-65.